Passion and purpose to transform patient journeys in anxiety and depression.

Mark Flather serves as Vice President, Corporate Strategy and Capital Markets. Mr. Flather has more than 25 years of capital markets experience in various capacities on both the buy-side and sell-side. Prior to joining Vistagen in March 2021, Mr. Flather managed the Investor Relations and Corporate Communications for Adamis Pharmaceuticals (Nasdaq: ADMP), a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas including allergy, opioid overdose, respiratory and inflammatory disease. While at Adamis, he was named on three different design patents for the company’s FDA-approved injection device platform. Prior to Adamis, Mr. Flather served as Vice President of Investor Relations and Outreach at MZ Group, a subsidiary of @titude Global, the world’s largest independent global IR consulting firm. Before MZ Group, Mr. Flather spent almost a decade as the Chief Operating Officer, Head Equity Trader, Investor Relations Director and Research Analyst for Hermes Advisors, a small to mid-cap equity hedge fund with an elite track record. Previously, he began his sell-side experience on the institutional sales and trading desk of the investment bank, Alex. Brown and Sons. Mr. Flather holds a B.A. in Psychology from U.C. Santa Barbara.